Long-term sedation with remimazolam besylate versus propofol in critically ill patients during invasive mechanical ventilation: a study protocol for a multicenter randomized non-inferior trial
- PMID: 37576823
- PMCID: PMC10416620
- DOI: 10.3389/fphar.2023.1139872
Long-term sedation with remimazolam besylate versus propofol in critically ill patients during invasive mechanical ventilation: a study protocol for a multicenter randomized non-inferior trial
Abstract
Background: Remimazolam besylate is a novel ultra-short-acting benzodiazepine that can potentially be a safe and effective sedative in intensive care units. This study aims to assess whether remimazolam besylate is not inferior to propofol in maintaining mild-to-moderate sedation in critically ill patients receiving long-term mechanical ventilation. Methods and analysis: This is a multicenter, randomized, single-blind, propofol-controlled, non-inferiority study. Eligible patients are randomly assigned to receive remimazolam besylate or propofol in a 1:1 ratio to maintain a Richmond Agitation-Sedation Scale score between -3 and 0. When patients are under-sedated, rescue sedation of dexmedetomidine is added. The primary outcome is the percentage of time in the target sedation range. The secondary outcomes are hours free from the invasive ventilator in 7 days, successful extubation in 7 days, and weaning time, the length of intensive care unit stay, the length of hospital stay, and mortality in 28 days. Modified intention-to-treat and safety analysis is performed. Clinical trial registration number: https://clinicaltrials.gov/ct2/show/NCT05555667.
Keywords: intensive care; mechanical ventilation; propofol; remimazolam; sedation.
Copyright © 2023 Yang, Tang, Du, Yu, Xu, Zhang, Liu, Zou, Ren, Yuan and Shang.
Conflict of interest statement
This study was sponsored by Yichang Humanwell Pharmaceutical Co., Ltd., China, who provided remimazolam besylate without charge for our study. Additionally, they contributed funds to hire a site management organization for this research project. They did not contribute to the design, analysis, and interpretation of the study. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Remimazolam Besylate Versus Propofol for Short-Term Sedation in Critically Ill Patients Receiving Mechanical Ventilation: Protocol for a Multicenter Randomized Non-inferior Trial.Adv Ther. 2025 Aug;42(8):4081-4088. doi: 10.1007/s12325-025-03268-7. Epub 2025 Jun 10. Adv Ther. 2025. PMID: 40493335
-
Remimazolam besylate versus propofol for long-term sedation during invasive mechanical ventilation: a pilot study.Crit Care. 2022 Sep 16;26(1):279. doi: 10.1186/s13054-022-04168-w. Crit Care. 2022. PMID: 36114552 Free PMC article. Clinical Trial.
-
Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study.Crit Care. 2023 Dec 4;27(1):474. doi: 10.1186/s13054-023-04760-8. Crit Care. 2023. PMID: 38049909 Free PMC article. Clinical Trial.
-
Effect of remimazolam besylate compared with propofol on the incidence of delirium after cardiac surgery: study protocol for a randomized trial.Trials. 2021 Oct 18;22(1):717. doi: 10.1186/s13063-021-05691-x. Trials. 2021. PMID: 34663423 Free PMC article.
-
Effectiveness of dexmedetomidine versus propofol on extubation times, length of stay and mortality rates in adult cardiac surgery patients: a systematic review and meta-analysis.JBI Database System Rev Implement Rep. 2018 May;16(5):1220-1239. doi: 10.11124/JBISRIR-2017-003488. JBI Database System Rev Implement Rep. 2018. PMID: 29762314
Cited by
-
Remimazolam Besylate Versus Propofol for Short-Term Sedation in Critically Ill Patients Receiving Mechanical Ventilation: Protocol for a Multicenter Randomized Non-inferior Trial.Adv Ther. 2025 Aug;42(8):4081-4088. doi: 10.1007/s12325-025-03268-7. Epub 2025 Jun 10. Adv Ther. 2025. PMID: 40493335
-
Safety and efficacy of remimazolam in mechanical ventilation in the ICU: a protocol for systematic evaluation and meta-analysis.BMJ Open. 2024 Dec 10;14(12):e091172. doi: 10.1136/bmjopen-2024-091172. BMJ Open. 2024. PMID: 39658293 Free PMC article.
References
-
- Antonik L. J., Goldwater D. R., Kilpatrick G. J., Tilbrook G. S., Borkett K. M. (2012). A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth. Analg. 115 (2), 274–283. 10.1213/ANE.0b013e31823f0c28 - DOI - PubMed
-
- Des B., Andreas K., Manu M., Morais R., Albrecht S., Jarnvig I. L., et al. (2005). Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: A randomised trial [ISRCTN47583497]. Crit. Care 9 (3), R200–R210. 10.1186/cc3495 - DOI - PMC - PubMed
-
- Devlin J. W., Skrobik Y., Gélinas C., Needham D. M., Slooter A. J. C., Pandharipande P. P., et al. (2018). Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit. Care Med. 46 (9), e825–e873. 10.1097/CCM.0000000000003299 - DOI - PubMed
Associated data
LinkOut - more resources
Full Text Sources
Medical